http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
B형간염 표면항체 양성인 환자에서 간이식 후 B형간염 재발에 대한 예방법으로서 B형간염 면역글로블린과 라미부딘의 효과 비교
이광웅(Kwang-Woong Lee),박재범(Jae Berm Park),조재원(Jae Won Joh),김성주(Sung Joo Kim),송건도(Geon Do Song),최성호(Seong Ho Choi),허진석(Jin Seok Heo),김용일(Yong Il Kim),이병붕(Byung Boong Lee),김정한(Jeong Han Kim),이석구(Suk Koo L 대한외과학회 2001 Annals of Surgical Treatment and Research Vol.60 No.6
한덕종 ( Duck Jong Han ),김송철 ( Song Cheol Kim ),박재범 ( Jae Berm Park ),김영훈 ( Young Hoon Kim ),박관태 ( Kwan Tae Park ),홍정자 ( Jung Ja Hong ),하희선 ( Hea Seon Ha ),정주희 ( Ju Hee Jung ),김인구 ( In Koo Kim ),박건춘 ( Ku 대한내과학회 2011 대한내과학회지 Vol.80 No.2
Background/Aims: Pancreas transplantation (PT) as the ultimate treatment for insulin-dependent diabetes has been the subject of debate clinically. Marked improvements in patient and graft survival, and decreases in postoperative morbidity have been achieved due to technical refinements, improved immunosuppressants, and better postoperative management. Here, we report our 18-year experience with PT performed at our institute. Methods: All recipients who underwent deceased donor or living donor PT between July 1992 and December 2009 were included. We reviewed the medical records, including operation records, progress, and laboratory findings during follow-up. Graft and patient survival were analyzed using the Kaplan-Meier method. Results: In total, 119 cases of pancreas transplantation were performed between July 1992 and December 2009 at our institute. Indications for pancreas transplantation were type I diabetes in 93 (78.2%) patients and type II diabetes in 16 (13.4%) patients. The transplanted pancreas was obtained from a deceased donor in 108 cases (90.8%) and a living donor in 11 cases (9.2%). Median follow-up duration was 39.3 months posttransplantation (range 0~176 months). Overall graft survival rates at 1, 5, and 10 years were 81.6%, 63.4%, and 57.1%, respectively. Following the introduction of tacrolimus as an immunosuppressant in 1999, graft survival at 1, 5, and 10 years was 89.1%, 72.9%, and 66.2%, and overall patient survival at 1, 5, and 10 years was 93.0%, 86.0%, and 86.%, respectively. Conclusions: Considering the quality of life and long-term patient survival, PT is an effective treatment strategy in non-obese diabetic patients requiring insulin regardless of the type of diabetes. (Korean J Med 2011;80:167-178)
태아의 간과 흉선 조직 그리고 조혈모 세포를 이식한 Rag2<SUP>-/-</SUP>γc<SUP>-/-</SUP> Mice에 사람의 면역 세포 형성
강미진(Mijin Kang),주성연(Sung-Yeon Joo),최봉금(Bong-Kum Choi),정다연(Da-Yeon Jung),최호인(Ho-In Choi),박재범(Jae Berm Park),최규성(Gyuseong Choi),권준혁(Choon Hyuck Kwon),김성주(Sung-Joo Kim),조재원(Jae-Won Joh) 대한외과학회 2008 Annals of Surgical Treatment and Research(ASRT) Vol.74 No.1
Purpose: Many researchers have tried to develop animal models that mimic the human immune system, e.g. a humanized mouse model, to improve the engraftment of hematopoietic stem cells and develop human immune cells in an animal model. This study evaluated the feasibility of the cultured human umbilical cord blood (hUCB)-derived CD34? cells for cell expansion, in Rag2<SUP>-/-</SUP>γc<SUP>-/-</SUP> mice, and establish co-transplantation with human fetal thymus/liver tissue (Thy/Liv) under the kidney capsule. Methods: Co-transplantation of hUCB-derived CD34? cells with Thy/Liv was performed. The hUCB-derived CD34? cells were prepared by freshly thawing (G1) and culturing for 7 days with two types of cytokine combinations (G2, G3). The CD45? cell populations were measured at 6, 8, 10 and 16 weeks in the peripheral blood. The splenocytes were cultured with mitogenic stimuli (PHA -L or IL-2) at 20 weeks posttransplantation, and the proliferation of human immune cells was evaluated. Results: There were no significant differences in the human CD45? cell populations at 6, 8, 10 and 16 weeks post-transplantation between the groups. In the cultured splenocytes at 20 weeks post-transplant with PHA-L or IL-2, there was remarkable expansion of CD3? cells in the three groups. Although no CD19? cells were detected in the spleen, human Ig G was detected in the sera of these mice. Conclusion: The cultured and expanded hUCB-derived cells with cytokine combinations might be a feasible cell source in humanized mouse modeling. In addition, human immune cells can be reconstituted from the co-transplantation of Thy/Liv and cultured hUCB-derived CD34? cells.
Rituximab와 혈장교환을 사용한 ABO 혈액형 부적합 생체 신장이식: 단일 기관의 경험
유훈 ( Hoon Yu ),김윤지 ( Yoon Ji Kim ),권석운 ( Seog Woon Kwon ),한덕종 ( Duck Jong Han ),박재범 ( Jae Berm Park ),박정식 ( Jung Sik Park ),정주희 ( Joo Hee Jung ),박수길 ( Su Kil Park ) 대한신장학회 2011 Kidney Research and Clinical Practice Vol.30 No.4
Purpose: ABO incompatibility had long been an obstacle in kidney transplantation. However, recent reports showed excellent outcomes. In this study, we evaluated the outcomes of ABO incompatible kidney transplantation with preconditioning protocol using rituximab and plasmapheresis. Methods: The recipients who had an ABO-incompatible donor and underwent living donor kidney transplantation were enrolled. Preconditioning protocol was pretransplant single dose rituximab with plasmapheresis at pretransplantation 7-10 days. Immune suppression regimen consisted of tacrolimus, mycophenolate mofetil and steroid. Anti-A or anti-B antibody titer was monitored during preconditioning and post transplantation period. Results: 37 patients underwent living donor ABO incompatible kidney transplantation. Median pre-treatment antibody titer was 1:64 and pre transplant antibody titer after 1-6 times of plasmapheresis was 1:2. Median follow-up duration was 332 days (range 156-681). One episode of acute T cell mediated rejection was observed. Mean serum creatinine at 2 weeks was 1.00±0.27 mg/dL and at 24 weeks was 1.21±0.37 mg/dL. Conclusion: ABO incompatible kidney transplantation with rituximab and plasmapheresis can be safely performed. It is therefore a valuable option for expanding donor pool and should be actively performed in Korea.
B형간염과 연관된 간세포암종의 근치적 절제술 후 혈관내피성장인자 아형의 발현양성 및 예후와의 관계
문주익 ( Ju Ik Moon ),김종만 ( Jong Man Kim ),정금오 ( Gum Oh Jung ),천재민 ( Jae Min Chun ),최규성 ( Gyu Seong Choi ),박재범 ( Jae Berm Park ),권준혁 ( Choon Hyuck David Kwon ),김성주 ( Sung Joo Kim ),조재원 ( Jae Won Jo ) 대한간학회 2008 Clinical and Molecular Hepatology(대한간학회지) Vol.14 No.2